Bristol Myers falls 3% despite positive cancer drug trial results

Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market’s reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met...